Carlsmed joined with the International Spine Study Group Foundation (ISSGF) to collect data on surgical treatment with personalized interbody devices. Long term outcomes data will be collected to assess the role of aprevo® devices in improving patient outcomes and reducing postoperative complications.
“Our partnership with the ISSGF and the inclusion of aprevo in the Complex Adult Deformity Surgery clinical study demonstrates the importance of clinical data collection in the treatment of patients with adult spinal deformity, ” said Mike Cordonnier, CEO of Carlsmed. “As Breakthrough technology, aprevo has been determined by FDA to provide for a more effective treatment than the current standard of care. We are committed to partnering with thought leaders in the mission to collect data and improve outcomes for patients with debilitating spine disorders.”
aprevo is reportedly the only available patient specific interbody technology. This study collaboration will compare the clinical, radiographic, and health-related quality of life outcomes between traditional stock devices and patient specific interbody devices in the treatment of adult spinal deformity.
Carlsmed joined with the International Spine Study Group Foundation (ISSGF) to collect data on surgical treatment with personalized interbody devices. Long term outcomes data will be collected to assess the role of aprevo® devices in improving patient outcomes and reducing postoperative complications.
"Our partnership with the ISSGF and the...
Carlsmed joined with the International Spine Study Group Foundation (ISSGF) to collect data on surgical treatment with personalized interbody devices. Long term outcomes data will be collected to assess the role of aprevo® devices in improving patient outcomes and reducing postoperative complications.
“Our partnership with the ISSGF and the inclusion of aprevo in the Complex Adult Deformity Surgery clinical study demonstrates the importance of clinical data collection in the treatment of patients with adult spinal deformity, ” said Mike Cordonnier, CEO of Carlsmed. “As Breakthrough technology, aprevo has been determined by FDA to provide for a more effective treatment than the current standard of care. We are committed to partnering with thought leaders in the mission to collect data and improve outcomes for patients with debilitating spine disorders.”
aprevo is reportedly the only available patient specific interbody technology. This study collaboration will compare the clinical, radiographic, and health-related quality of life outcomes between traditional stock devices and patient specific interbody devices in the treatment of adult spinal deformity.
Copy to clipboard 
